Novartis Oncology is investigating the PI3K/AKT/mTOR pathway to understand and treat advanced breast cancer.
Exploring the PI3K/AKT/mTOR Pathway
A new MIT study explains why dendritic cells (green) in lymph nodes that drain from the lungs fail to stimulate killer T cells (white) to attack lung tumors. [MIT]
